| Reference |
|---|
Eichenfield L, Ganslandt C, Kurvits M, Schlessinger J. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol. 2015;32:28-35 pubmed publisher |
Jabbar Lopez Z, Wu K, Reynolds N. Newer agents for psoriasis in adults. BMJ. 2014;349:g4026 pubmed publisher |
Karthaus N, van Spriel A, Looman M, Chen S, Spilgies L, Lieben L, et al. Vitamin D controls murine and human plasmacytoid dendritic cell function. J Invest Dermatol. 2014;134:1255-1264 pubmed publisher |
Al Jaderi Z, Maghazachi A. Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins (Basel). 2013;5:1932-47 pubmed publisher |
Park J, Mun J, Jwa S, Song M, Kim H, Ko H, et al. Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: an open-label study. J Am Acad Dermatol. 2013;69:492-3 pubmed publisher |
Abdelmaksood R, Hashad D. The impact of topical calcipotriol and betamethasone on human beta-defensin 2 expression and serum level in psoriatic patients. Clin Lab. 2013;59:277-82 pubmed |
Ding N, Yu R, Subramaniam N, Sherman M, Wilson C, Rao R, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601-13 pubmed publisher |
Monroe J. Progressive changes in facial pigmentation. JAAPA. 2013;26:12 pubmed |
Akdeniz N, Yavuz I, Gunes Bilgili S, Ozaydın Yavuz G, Calka O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo. J Dermatolog Treat. 2014;25:196-9 pubmed publisher |
Menter A, Gold L, Bukhalo M, Grekin S, Kempers S, Boyce B, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013;12:92-8 pubmed |
Pommergaard H, Burcharth J, Rosenberg J, Raskov H. Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice. Cancer Invest. 2013;31:92-6 pubmed publisher |
Zarkik S, Benzekri L, Elfazazi H, Dehayni M, Hassam B. [Efficacy of calcipotriol ointment in nevoid keratosis of the nipple]. Ann Dermatol Venereol. 2012;139:739-40 pubmed publisher |
Abramovits W, Oquendo M, Scheinfeld N, Gupta A. Sorilux (calcipotriene) foam 0.005%. Skinmed. 2012;10:301-4 pubmed |
Girolomoni G, Vena G, Ayala F, Cannavo S, de Pita O, Chimenti S, et al. Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol. 2012;147:609-24 pubmed |
Tirado Sanchez A, Ponce Olivera R. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Cutis. 2012;90:140-4 pubmed |
Meephansan J, Komine M, Tsuda H, Ohtsuki M. Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line. Clin Exp Dermatol. 2012;37:889-96 pubmed publisher |
Wong J, Davis S, Feldman S, Koo J. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012;11:957-62 pubmed |
Queille Roussel C, Hoffmann V, Ganslandt C, Hansen K. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Clin Drug Investig. 2012;32:613-9 pubmed publisher |
Leyva Castillo J, Hener P, Jiang H, Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol. 2013;133:154-63 pubmed publisher |
Urbina F, Sudy E, Misad C. Two episodes of axillary granular parakeratosis triggered by different causes: case report. Acta Dermatovenerol Croat. 2012;20:105-7 pubmed |
Feldman S, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol. 2012;13:261-71 pubmed publisher |
Gauld N, Emmerton L, Kelly F, Buetow S. A new model of prescription to nonprescription reclassification: the calcipotriol case study. Clin Ther. 2012;34:1324-32 pubmed publisher |
Kapila S, Hong E, Fischer G. A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis. Australas J Dermatol. 2012;53:98-105 pubmed publisher |
Knudsen N, Rønholt S, Salte R, Jorgensen L, Thormann T, Basse L, et al. Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm. 2012;81:532-9 pubmed publisher |
Ozkan I, Kose O, Ozmen I, Arca E. Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis. Int J Dermatol. 2012;51:609-13 pubmed publisher |
Knudsen N, Schiffelers R, Jorgensen L, Hansen J, Frokjaer S, Foged C. Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α₂β₁ receptor. Int J Pharm. 2012;428:171-7 pubmed publisher |
Umezawa Y, Mabuch T, Ozawa A. Generalized pustular psoriasis in a child: observation of long-term combination therapy with etretinate and calcipotriol for 16 years. Pediatr Dermatol. 2012;29:206-8 pubmed publisher |
Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka Baran A, et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132:1416-24 pubmed publisher |
Sato Deguchi E, Imafuku S, Chou B, Ishii K, Hiromatsu K, Nakayama J. Topical vitamin D? analogues induce thymic stromal lymphopoietin and cathelicidin in psoriatic skin lesions. Br J Dermatol. 2012;167:77-84 pubmed publisher |
Rogalski C, Grunewald S, Schetschorke M, Bodendorf M, Kauer F, Simon J, et al. Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol. Int J Hyperthermia. 2012;28:184-90 pubmed publisher |
|
|
